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Abstract. The metastatic lymph node 64 (MLN64) gene was
initially identified as highly expressed in the metastatic
lymph node from breast cancer. It is localized in q12-q21 of
the human chromosome 17 and is often co-amplified with
erbB-2. However, the role played by MLN64 in breast cancer
remains unclear. In the present study, the expression of MLN64
was examined in a breast cancer cohort using quantitative
real-time PCR and immunohistochemical staining. It demon-
strated that MLN64 was highly expressed in breast tumours
compared to corresponding background tissues at both
transcript level and protein level. The elevated level of MLN64
transcripts was correlated with the poor prognosis and overall
survival of the patients. A panel of breast cancer cell sublines
was subsequently developed by knockdown of MLN64
expression. Loss of MLN64 expression in MCF-7 cells
resulted in a significant reduction of cell growth (absorbance
for MCF-7ΔMLN64 being 0.87±0.07, P<0.01 vs. wild-type control
(MCF-7WT 1.13±0.06) and transfection control (MCF-7pEF
1.27±0.05). In cell-matrix adhesion assay, MDA-MB-231ΔMLN64
cells showed a significant increase in adhesion (86±14),
p<0.01 compared with both MDA-MB-231WT (61±20) and
MDA-MB-231pEF (45±27). Further investigations demonstrated
an increase in protein level of the focal adhesion kinase
(FAK) in MDA-MB-231ΔMLN64 cells using Western blot
analysis and immunofluorescent staining of FAK. Moreover,
addition of FAK inhibitor to these cells diminished the effect
of MLN64 on cell-matrix adhesion, suggesting that FAK
contributed to the increased adhesion in MDA-MB-231ΔMLN64
cells. In conclusion, MLN64 is overexpressed in breast
cancer, and its level correlates with poor prognosis and
patient survival. MLN64 contributes to the development and
progression of breast cancer through the regulation of cell
proliferation and adhesive capacity.
Introduction
Breast cancer is the most common cancer in women in Europe
and North America affecting up to one in eight women over
their lifetime (1). Despite recent advances made in diagnosis
and treatment, breast cancer remains the leading cause of
cancer-related mortality in women.
MLN64 (metastatic lymph node 64), which was initially
identified from a breast cancer-derived metastatic lymph
node cDNA library, has been localized to the q12-q21 of the
long arm of chromosome 17 (2). MLN64 gene encodes a 445
amino-residue protein containing two distinct domains. Its N-
terminus consists of a MENTAL (MLN64 N-Terminal)
domain similar to MLN64 N-terminal homologue (MENTHO),
containing four potential transmembrane regions and target
the protein to the membrane of late endosome (3). By immuno-
cytofluorescent staining, MLN64 protein was observed to be
localized within bundle-like structures distributed throughout
the cell cytoplasm and condensed in a perinuclear patch. If its
N-terminus was removed, MLN64 was homogeneously
distributed in the cytoplasm, suggesting that N-terminus
acts on the specific cytoplasmic localization of MLN64 (4).
Its C-terminus contains a StAR-related transfer domain
(START) that is highly homologous to steroidogenic acute
regulatory protein (StAR) (4). StAR is a mitochondrial protein
involved in the acute synthesis of steroids in adrenal and
gonad (5). Homology between these molecules further
raises the possibility that MLN64 has steroidogenic
activity. X-ray crystallography indicates that the START
domain, like StAR protein, forms a hydrophobic tunnel
structure that can bind a single cholesterol molecule (6-8).
Recent evidence suggests that MLN64 plays a key role in
steroidogenesis by enhancing the cholesterol transport at the
surface of late endosome (2,4,9,10). Moreover, MLN64 has
been proposed to mediate StAR-independent steroidogenesis,
because MLN64 mRNA was detected in some tissues, such as
placenta and brain, which produce steroid hormones but do not
express StAR (10).
Amplification of certain region in chromosome 17q has
been indicated in various solid tumours, including breast
cancer, prostate cancer and upper gastrointestinal adenocarci-
nomas (2,11,12). This region encodes various genes which play
critical roles in carcinogenesis and disease progression, such
as ERBB2, GRB7 (growth factor receptor-bound protein 7) and
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MLN64. The amplification can be observed in 20-30% breast
cancers within the region of chromosome 17q12, containing
MLN64 gene (1). MLN64 is highly expressed in certain
breast carcinomas, often co-amplified with erbB-2, and thus
may contribute to the development and progression of breast
tumours by mediating the intratumoral steroidogenesis
(2,13-15). The elevated expression of MLN64 has also been
demonstrated in prostate cancer which is co-expressed with
CYP-17. CYP-17 encodes a key enzyme in androgen synthesis
(12).
Although overexpression of MLN64 has been indicated in
certain solid tumours, its biological function in tumour cells
and how it is involved in the disease progression remain
largely unknown. In the present study, we investigated the
functional aspect of MLN64 in breast cancer cells after
creating sublines of breast cancer cells in which MLN64 was
knocked down using specific ribozyme transgenes. The
expression of MLN64 was also examined in a breast cancer
cohort, and analysed against the clinical aspects.
Materials and methods
Cell lines and cells culture. Human breast cancer cell lines,
MDA-MB-231 and MCF-7 were obtained from the European
Collection of Animal Cell Cultures (ECACC, Salisbury,
England). Cells were routinely cultured with Dulbecco's
modified Eagle's medium containing 10% fetal calf serum,
100 U/ml penicillin and 100 μg/ml streptomycin at 37°C and
5% carbon dioxide.
Human breast specimens. A total of 146 breast samples were
collected immediately after surgery and stored at -80°C until
use, with approval of the local ethics committee. It included
113 breast cancer tissue and 33 background normal breast
tissues which were from the same patients. All the specimens
used in the current study were verified by a consultant patho-
logist. Patients were routinely followed clinically after surgery
and details were stored in a database. The median follow-up
period was 120 months. The clinical data are provided in
Table I.
Immunohistochemical staining of MLN64. Frozen specimens
of mammary tissues were cut at a thickness of 6 μm using a
cryostat (Leica CM 1900, Leica Microsystems UK Ltd.,
Buckinghamshire, UK). The sections were mounted on super
frost plus microscope slides, air dried and then fixed in the
mixture of 50% acetone and 50% methanol for 15 min. After
10-min air-drying, the slides were placed into OptiMax Wash
Buffer (BioGenex, San Ramon, USA) for 5 min to rehydrate.
The slides were incubated for 20 min in a blocking solution
that contained 10% horse serum and probed with anti-MLN64
antibody (Santa Cruz Biotechnology) for 1 h. Following
extensive washing, the slides were incubated for 30 min with
a biotinylated secondary antibody (Multilink swine anti-
goat/mouse/rabbit immunoglobulin, Dako Inc. Carpinteria,
CA). After washing, slides were placed in avidin-biotin
complex (ABC-Vector Labs) for 30 min. Diaminobenzidine
chromogen (Vector Labs) was then added to the slides and
incubated in the dark for 5 min. The slides were counterstained
with Mayer's haematoxylin for 1 min and dehydrated in
ascending grades of ethanol before clearing in xylene and
mounting under a cover slip.
Reverse transcription-PCR. Total RNA extraction from
frozen tissues and culture cells was performed using Total
RNA Isolation Reagent (ABgene, Epsom, UK). The concen-
tration of RNA was determined using an ultraviolet spectro-
photometer. Routine RT-PCR was carried out using a PCR
master mix that was commercially available (AbGene), then
run in a GeneAmp PCR System 2400 thermocycler (Perkin-
Elmer). The sequences of primers used were: MLN64: 5'-GC
ACCTTTGTCTGGATTCTT-'3 and 5'-TGAAAGGCAAAT
TCAAACAT'-3.
Reactions were carried out at the following conditions:
94°C for 5 min, 35 cycles of 94°C for 30 sec, 55°C for 30 sec
and 72°C for 30 sec, followed by a final extension of 5 min
at 72°C. PCR products were separated on a 2% agarose gel
and photographed using a digital camera mounted over a UV
transilluminator after a staining with ethidium brominde. The
quality of cDNA was verified using GAPDH primers (5'-AGC
TTGTCATCAATGGAAAT-3' and 5'-CTTCACCACCTTC
TTGATGT-3').
Real-time quantitative PCR. The level of MLN64 transcripts
from the prepared cDNA was determined using a real-time
quantitative PCR, based on Amplifluor technology, modified
from a method reported previously (16). An additional
sequence was added to one of the primers, known as the Z
sequence (5'-actgaacctgaccgtaca-3') which is complementary
to the universal Z probe (Intergen Inc., Oxford, UK). The
reaction was carried out on IcyclerIQ™ (Bio-Rad, Hemel
Hemstead, UK) which is equipped with an optic unit that
allows real-time detection of 96 reactions. The reaction
condition was: 94°C for 12 min, 50 cycles of 94°C for 15 sec,
55°C for 40 sec (the data capture step) and 72°C for 20 sec.
The levels of the transcripts were generated from an internal
standard that was simultaneously amplified with the samples.
Construction of ribozyme transgene targeting human MLN64
and the establishment of corresponding stable transfectants.
Anti-human MLN64 hammerhead ribozymes were designed
based on the secondary structure of the gene generated using
the Zuker RNA mFold program (17). The ribozymes were
accordingly synthesized and then cloned into pEF6/V5-His
TOPO vector (Invitrogen, Paisley, UK). The verified ribozyme
transgenes and empty plasmids were transfected into MDA-
MB-231 and MCF-7 cells respectively using an Easyjet Plus
electroporator (EquiBio, Kent, UK). After up to 14 days of
selection with 5 μg/ml blasticidin, the verified transfectants
were cultured in maintainence medium containing 0.5 μg/ml
blasticidin. Primer sequences of the ribozymes were 5'-CTG
CAGGTGCGAGGAGAGGCTCTGGCTGTGGCTGATGA
GTCCGTGAGGA-3' and 5'-ACTAGTGGCCTCCCTGGTC
CTCACTGTTTCGTCCTCACGGACT-3'.
Cell growth assay (18). Breast cancer cells were plated into
96-well plates at 3,000 cells/well. Cells were fixed in 4%
formaldehyde on the day of 1, 3, 5 after plating. The cells were
then stained with 0.5% (w/v) crystal violet. Following washing,
stained crystal violet was extracted with 10% (v/v) acetic
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acid. Absorbance was determined at a wavelength of 540 nm
using an ELx800 spectrophotometer.
Flow cytometric analysis of apoptosis (19). All cells including
those floating in the culture medium were harvested after a
period of incubation. Cells were washed in cold PBS and
resuspended in 1X annexin-binding buffer at a density of
1x106 cells/ml after centrifugation. FITC annexin V (5 μl) and
1 μl of the PI working solution (100 μg/ml) (Molecular Probes,
Oregon, USA) were added to 100 μl of the cell suspension.
After a 15 min incubation at room temperature, 400 μl of 1X
annexin-binding buffer was added, mixed gently and the
samples were kept on ice. The stained cells were immediately
analyzed using the flow cytometer and FlowMax software
package.
Cell matrix adhesion. Cells (30,000) were added to each
well of a 96-well plate which was pre-coated with Matrigel
(5 μg/well) (BD Biosciences, Oxford, UK). After 40 min of
incubation, non-adherent cells were washed off using BSS
buffer. The remaining cells were fixed with formalin and
stained with crystal violet. The number of adherent cells was
then counted. When the effect of FAK on adhesion was
studied, 10 nM FAK inhibitor (PF573228, Tocris, Bristol,
UK) was added in the corresponding wells.
In vitro invasion assay. This was performed as previously
reported and modified in our laboratory (20). Briefly,
transwell inserts (upper chamber) with 8 μm pores were
coated with 50 μg/insert of Matrigel and air-dried, before
being rehydrated. Cells (30,000) were seeded into each well.
After 72 h, cells that had migrated through the matrix and
adhered on the other side of the insert were fixed and stained
with crystal violet. The crystal violet was extracted with 10%
(v/v) of acetic acid and the absorbance was obtained using a
spectrophotometer.
In vitro motility assay using cytodex-2 beads. This was based
on a method reported previously (20). Cells (1x106) were
incubated with 100 μl cytodex-2 beads (Pharmacia, Pisca-
taway, NJ) in 10 ml DMEM overnight. After washing, the
beads with adhered cells were resuspended in 1 ml of DMEM.
Cell suspension (100 μl) were transferred into each well of a
24-well plate. After 4 h of incubation, the beads were washed
off using BSS. The migrated cells were then fixed and stained
with crystal violet for counting.
In vitro migration/wounding assay. Cells were seeded into a
24-well plate and allowed to reach confluence. The cell
monolayer was scraped using a fine gauge needle to create a
wound of approximately 200 mm wide (21). The migration
of cells to close the wound was then recorded and examined
microscopically (Leitz DMIRB) on a heated stage using a
time-lapse video recording facility. Images of wound closure
between the two leading cell fronts were subsequently obtained
at 30 min intervals and analyzed using an image analysis
software Optimas (Version 6, Optimas, UK).
Electric cell-substrate impedance sensing (ECIS) based
cellular adhesion assay. The 9600 model of the ECIS
instrument (Applied Biophysics Inc., NJ, USA) were used for
adhesion assay in the study, as previously reported (22-24).
The 8W10E arrays (8 wells, 10 electrodes in each well) were
used in the present study. Following a pretreatment with
L-cysteine solution, the arrays were incubated with the
medium for 1 h. MDA-MB-231wt, MDA-MB-231pEF, MDA-
MB-231ΔMLN64 cells were seeded at 300,000 per well in 400 μl
medium. The impedance at 30 kHZ was recorded for 2.5 h
and the data was analysed using ECIS-9600 system.
Immunofluorescence staining of paxillin and FAK. Cells
were seeded on chamber slides (Nunc™) at 20,000 cells per
well. After 60 min of incubation, the cells were fixed in ice-
cold ethanol for 20 min and then rehydrated with BSS buffer
and permeabilized before staining. Anti-paxillin or anti-FAK
antibody (BD Biosciences Pharmingen) was added and
incubated for 1 h. Then specific FITC labelled secondary
antibody (Dako, Glostrup, Denmark) was used to react in the
dark for 1 h. Fluorescent staining was visualized using an
Olympus™ BX51 microscope and imaged using a cooled
C4742-80 digital camera (Hamamatsu Photonics UK, Welwyn
Garden City, UK).
Western blot analysis of MLN64 and FAK. Cells were
collected and lysed in HCMF buffer (25). The protein concen-
tration was quantified using DC Protein Assay kit (Bio-
Rad™) and an ELx800 spectrophotometer (Bio-Tek®). Equal
amounts of protein from each sample (20 μg/lane) were
added onto a 10% sodium dodecyl sulfate-polyacrylamide
gel. After electrophoresis, proteins were blotted onto nitro-
cellulose sheet and blocked in 10% skimmed milk for 60 min.
Proteins were probed with the anti-human MLN64 and FAK
antibody and the corresponding peroxidase-conjugated
secondary antibodies. A molecular weight marker (SDS-6H;
Sigma Chemical Co.) was used to determine the protein size.
Protein bands were visualized with a Super-signal™ West
Dura system and documented using a gel documentation
system (UVITech, Cambridge, UK).
Statistical analysis. Statistical analysis was performed using
SPSS. Mann-Whitney U-test was used for analysis of non-
normally distributed data, while t-test was used for normally
distributed. Survival was analyzed using Kaplan-Meier survival
analysis. P<0.05 was considered statistically significant.
Results
The expression of MLN64 was examined in a variety of
breast cancer cells using RT-PCR. Higher level of transcript
expression was seen in breast cancer cells and the breast
cancer tissue, compared with the normal mammary background
tissue (Fig. 1B). Interestingly, we found that in some normal
human cell lines (HECV, MRC-5) MLN64 transcripts were
also detectable. Similar result was found in the real-time quanti-
tative PCR (Fig. 1C). Breast cancer tissue had higher level of
transcripts (median 1.08 copies) compared with normal mam-
mary tissues (median 0.50 copies), but the difference was not
statistically significant (P=0.13).
Immunohistochemical staining of MLN64 protein was
observed in the human breast tissue section (n=32 pairs).
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MLN64 protein was detected to be strongly stained in the
cytoplasm of breast cancer cells in the specimen, while in the
adjacent normal breast tissues, only little staining was seen
(Fig. 1A). This pattern is consistent with the observation with
the increased level of MLN64 transcripts seen in both breast
cancer tissues and cell lines (Fig. 1B and C).
The level of MLN64 transcripts was analysed against the
corresponding clinical and pathological data (Table I). We
also assessed MLN64 transcript levels in relation with
clinical TNM staging except for the TNM4 group due to low
sample number in the group (n=4). MLN64 levels were lower
in tumours of early stage (TNM1, median, 0.61 copies), and
were increased in the tumours of the advanced P=0.018 and
0.015, compared with TNM2 (median, 2.56 copies) and
TNM3 (median, 4.09 copies), respectively. Therefore, MLN64
expression was correlated with tumour spread. The relationship
between the levels of MLN64 transcripts and histological
types and nodal status were also analysed (Table I). Tumours
with lymphatic involvement had higher levels of MLN64
transcripts than the node negative tumours. Although there
was some elevated expression of MLN64 seen in the poorly
differentiated tumours, but the differences were not statis-
tically significant when compared with well differentiated and
moderately differentiated tumours.
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Figure 1. MLN64 expression in breast cancer tissue and cell lines. (A) Immunohistochemical staining of MLN64 in normal mammary tissues (left panel) and
tumour tissues (right panel) with different magnifications in the same region. (B) Detection of the MLN64 transcripts in different cell lines and breast tissue
specimens using RT-PCR. GAPDH was used as the housekeeping control. (C) Quantitative analysis of MLN64 transcripts in normal and tumour tissues with
Q-PCR.
Figure 2. MLN64 expression and clinical outcome and long-term survival.
(A) Expression level of MLN64 and clinical outcome. The MLN64 trans-
cripts levels in patients disease-free are lower than those patients who had
poor outcome (p=0.001), including local recurrence, metastases and died of
breast cancer. (B) Kaplan-Meier survival curves: the overall survival of
patients who had lower level of MLN64 transcripts was better than those
patients with higher expression (p=0.012).
Figure 3. Knockdown of MLN64 expression in two breast cancer cell lines.
RT-PCR shows MLN64 suppression at the mRNA level in the MDA-MB-231
(left) and MCF-7 (right) cell lines.
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Using the Nottingham Prognostic Index, we further
analysed the relationship between prognosis and MLN64
expression (Table I). Patients with moderate prognosis (NPI
3.4-5.4, median 1.30 copies) and poor prognosis (NPI >5.4,
median 1.20 copies) exhibited higher levels, p=0.309 and
p=0.248 when compared to the good prognosis [(NPI<3.4)
patients (median 0.83 copies), respectively)]. Using clinical
outcomes over the 10 year follow-up period, MLN64 was
found to be elevated in those with poor outcomes including
local recurrence, metastasis or died of breast cancer (median
4.70), p=0.0001 compared with those who were disease-free
(median 0.55).
To investigate whether MLN64 expression levels were
correlated with the long-term survival, we divided the
patients into two groups according to their MLN64 transcript
levels. Kaplan-Meier survival analysis demonstrated that
patients with higher level of MLN64 transcripts had shorter
overall survival (Fig. 2). The average overall survival of
patients with higher MLN64 expression was 89.3 months
(95% confidence interval 58.3-120.3 months), p=0.012, in
comparison with 138.9 months in patients with lower
expression level (95% confidence interval 129.3-148.4
months).
The expression of MLN64 was knocked down using
ribozyme transgenes targeting human MLN64 mRNA. This
was performed in two breast cancer cell types, MCF-7 and
MDA-MB-231, which expressed MLN64 (Fig. 1) The
knockdown of MLN64 was verified in the transfectants using
RT-PCR (Fig. 3). Marked reduction of MLN64 expression
was seen in both MDA-MB231ΔMLN64 and MCF-7ΔMLN64 cells
which were transfected with ribozyme transgenes, compared to
their corresponding controls including wild-type and empty
plasmid controls.
The effect of knocking down MLN64 on in vitro cell
functions were examined including cell growth, adhesion,
invasion, motility and migration. Loss of MLN64 in MDA-
MB-231 cells had a significant impact on cell matrix adhesion
(Fig. 4A). The MDA-MB-231ΔMLN64 cells exhibited a signifi-
cantly stronger adhesion ability (adherent cell number 86±14),
p<0.01 compared with both MDA-MB-231WT (56±17) and
MDA-MB-231pEF cells (45±29). However, this effect was not
seen in MCF-7ΔMLN64 cells (data not shown). Moreover, in
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Table I. Breast cancer patients clinical data details and MLN64 transcript levels.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Clinical/pathological features Sample Median IQR P-value
no. (copy no.)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Grade
1 20 2.07 0.28-3.26
2 39 1.00 0.19-4.70 0.614
3 52 0.87 0.19-7.37 0.758
NPI
1  (<3.5) 59 0.83 0.16-3.89
2  (3.5-5.4) 35 1.30 0.27-3.74 0.309
3  (>5.4) 15 1.20 0.2-11.0 0.248
TNM
1 61 0.61 0.17-2.72
2 36 2.56 0.21-11.3 0.018
3 7 4.09 1.14-27.5 0.015
4 4 0 0-302
Clinical outcome
Disease-free 81 0.55 0.15-2.86
Poor outcome
With metastasis 5
With local recurrence 4 4.70 1.2-12.6 0.0001
Died of breast cancer 16
Histology
Ductal 89 1.01 0.19-4.44 0.396
Lobular 11 1.18 0.54-6.28
Others 6 2.90 1.56-6.53
Lymph node status
Negative 59 0.83 0.16-3.89 0.28
Positive 50 1.24 0.25-6.30
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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migration, motility and invasion assays, knockdown of MLN64
in the cell lines did not show any obvious difference in
comparison with the corresponding controls (data not shown).
In contrast, knockdown of MLN64 reduced the in vitro
growth of MCF-7 cells, but not in the MDA-MB-231 cells
(Fig. 4B). The absorbance of MCF-7ΔMLN64 at day 5 was
0.84±0.27, p<0.01 compared to MCF-7WT cells (1.43±0.26)
and MCF-7pEF cells (1.65±0.29), respectively. There were no
differences in cell cycle and apopotosis between the control
and MLN64 knockdown cells (data not shown).
To further evaluate the effect on adhesion by MLN64
knockdown in MDA-MB-231 cells, we adopted the Electric
Cell Impedance Sensing (ECIS) method. As shown in Fig. 4C,
the MDA-MB-231ΔMLN64 cells showed a dramatically increased
adhesion when compared with the control cells, as shown by
a rapid rise in impedance, thus indicating stronger attachment
ability to the electrode. The impedance of MDA-MB-231ΔMLN64
cells at 160 min after seeding was 298±30 ohms which was
significantly higher than that of MDA-MB-231WT (114±25
ohms) and MDA-MB-231pEF cells (137±29 ohms), p<0.01 for
both comparisons (Fig. 4D).
From the adhesion assay in vitro and the ECIS assay, we
found that suppression of MLN64 expression made the
adhesion ability stronger in MDA-MB-231 cells. We further
assessed downstream events following cell adhesion to the
matrix surface by staining for 2 matrix adhesion regulatory
molecules, paxillin and FAK. Staining for FAK in MDA-
MB-231ΔMLN64 cells was dramatically enhanced at focal
adhesion sites (Fig. 5A). Interestingly, there was no difference
in the staining for paxillin in three sublines of MDA-MB-231
cells. Interestingly, in MCF-7 cells, there were rather strong
staining signals for both FAK and paxillin at focal
adhesion sites. FAK staining in MCF-7ΔMLN64 cells had a
little weaker signal compared to the MCF-7WT and MCF-7pEF
cells (Fig. 5A). Using Western blot analysis, a significantly
higher protein expression was seen in the MDA-MB-
231ΔMLN64  cells compared to both control cells (Fig. 5B).
A FAK inhibitor was then employed to assure the involve-
ment of FAK in the regulation of adhesion by MLN64 in
MDA-MB-231 cells. The FAK inhibitor (10 nM) diminished
the effect of MLN64 knockdown on cell-matrix adhesion in
MDA-MB-231 cells. When there was no FAK inhibitor
added, MDA-MB-231ΔMLN64 cells still had a significant increase
(118.0±10.9) in adhesion compared with both wild-type
(78.9±11.1) and plasmid control (89.5±8.8). In exposure to
FAK inhibitor (10 nM), the number of adherent cells was
reduced to 68±12.6 for MDA-MB-231ΔMLN64 cells which was
down to a similar level of both MDA-MB-231WT (60.9±19.0)
and MDA-MB-231pEF (60.4±11.8) controls (Fig. 6).
Discussion
MLN64, reported first by Tomasetto et al (2), appears to be
involved in cholesterol hemeostasis and steroidogenesis
(4,9,10,26-28). Moreover, it is suggested that MLN64 was
overexpressed in some invasive breast cancers (14%), and
breast cancer metastases (43%) (4). Immunoblot analysis
from the same authors has shown that that expression of
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Figure 4. Influences on cell function by knockdown of MLN64 in breast cancer cells. (A) Adhension in MDA-MB-231 cells. MDA-MB-231ΔMLN64 cells
exhibited the enhanced adhesiveness. (B) Cell growth in MCF-7 cells. MCF-7ΔMLN64 cells had a reduction in cell growth. **p<0.01. (C) MLN64 knocked down
on cell adhesion as analysed by ECIS. In the MDA-MB-231 cells which were knocked down MLN64 showed a markedly increased adhesion. (D) A
significant increase of adhesion in MDA-MB-231ΔMLN64 cells shown as the resistance at 2.5 h using ECIS, n=6, **p<0.01 vs. MDA-MB231WT and MDA-
MB231pEF controls.
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MLN64 protein exists in most breast cancer cell lines and
breast cancer tissues, as well as in an ovary carcinoma cell
line. The present study has also shown a dramatically stronger
staining of MLN64 seen in breast cancer specimens
compared to normal breast tissues and the presence of MLN64
in breast cancer cell lines.
MLN64 is frequently coamplified and expressed with
ERBB2 oncogene (2) and has been reported to correlate with
breast patient prognosis. High expression of MLN64 correlated
significantly with a short overall survival (OS) and disease-
free survival (DFS). MLN64 is thus considered as a useful
predictor for breast cancer (13). In the prostate cancer
MLN64 expression seems to be correlated with high stage,
high Gleason score and short relapse-free time in the prostate
cancer patients (12). In the current study, the levels of
MLN64 transcript in a breast cancer cohort were analysed
against the corresponding clinical and pathological data. The
result showed that patients with higher TNM staging or poor
clinical outcome (with metastasis, local recurrence and died of
breast cancer) had a relatively higher level of MLN64
expression. Moreover, the patients with higher MLN64
expression had a lower overall survival comparing to those
with lower expression. Collectively, these clinical findings
lead to a hypothesis that autonomous steroidogenesis can be
present in the neoplastic tissue and that MLN64 may be
implicated in an intratumoral steroidogenic process resulting
in cancer progression (4).
Biological function of MLN64, especially its role in
breast cancer, is far from clear. Our present study has
revealed diverse roles played by MLN64 in breast cancer cells.
Knockdown of MLN64 in MCF-7 cells lead to a reduction
of in vitro cell growth, but this effect was not seen in the
MDA-MB-231 cells. A recent study also demonstrated a
positive role of MLN64 on proliferation of breast cancer cells
(SKBR3 and BT474) (1). It suggests MLN64 can promote the
cell proliferation thus contributing to the tumour growth at
both primary and secondary sites. We examined the effect of
MLN64 knockdown on cell cycle using a flow cytometry
method. There was no obvious change seen in the cell cycle.
The most interesting observation from in vitro function
assays was the alteration on cell-matrix adhesion by MDA-
MB-231ΔMLN64 cells. The MDA-MB-231 cells became more
adhesive when their MLN64 expression was suppressed by
the ribozyme transgenes. This effect was seen in MDA-MB-
231 cells using both cell-matrix adhesion assay and ECIS
assay, but not in MCF-7 cells. Cell adhesion to extracellular
matrix is predominantly regulated by the integrin signalling
system. FAK is non-receptor tyrosine protein kinase
localizing in cytoplasm that can be activated by integrin-
ligand complex. FAK and paxillin can bind the trans-
membrane-integrin and cytoskeleton proteins, resulting in the
connection of extracellular matrix and cytoskeleton to
produce cell adhesion. It was reported that increased levels of
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Figure 5. Effect on adhesion regulatory molecules by knockdown of MLN64. (A) Immunofluorescent staining of FAK and paxillin, which are indicated by
arrows. Dramatically enhanced straining of FAK was seen in MDA-MB-231ΔMLN64 cells compared to MDA-MB-231WT and MDA-MB-231pEF cells. (B)
Western blot analysis of FAK. MDA-MB-231ΔMLN64 cells showed a significantly elevated protein expression of FAK compare with both controls (top bands).
A reduced protein level of MLN64 was also confirmed in MDA-MB-231ΔMLN64 cells compared to the controls using the Western blotting (the bands in the
middle).
Figure 6. FAK inhibitor impaired the effect of cell adhesion by MLN64
knockdown in MDA-MB-231 cells.
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FAK were found in 85% (17 of 20) invasive tumours, and in
100% (all 15) metastatic tumours, suggesting that FAK
overexpression may accompany changes in signal pathways
involved in tumour cell invasion and metastasis (29). To
elucidate the mechanism of the effect on adhesion, we
examined two key molecules involved in the cell-matrix
adhesion, focal adhesion kinase (FAK) and paxillin. The
immunofluorescent staining showed a dramatically strong
FAK staining in MLN64 knockdown cells while there was
no signal exhibited by the wild-type and pEF-control cells.
Western blot analysis also revealed an increase in the level of
FAK protein in the MDA-MB-231ΔMLN64 compared to both
controls. The effect on FAK was not seen in MCF-7 cells in
which stronger staining of both FAK and paxillin was
exhibited. This is consistent with the observations from cell-
matrix adhesion assays and indicates that MLN64 may
participate in the regulation of cell-matrix adhesion in MDA-
MB-231 cells via FAK. This notion is supported by the
experiments using a FAK inhibitor which diminished the
effect of MLN64 knockdown on cell adhesion in MDA-MB-
231 cells.
In conclusion, MLN64 is overexpressed in breast cancer.
Higher expression level of MLN64 is correlated with poor
prognosis and overall survival. Moreover, MLN64 can reduce
the ability of adhesion of MDA-MB-231 cells and promote
the growth in MCF-7 cell lines. We have further provided
evidence to show that expression of MLN64 enabled the
breast cancer cells to impair the cell-matrix adhesion via
regulating the intergin-mediating FAK signalling pathway.
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